Serum lactate dehydrogenase to alanine aminotransferase ratio as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. | Synapse
March 13, 2026
Serum lactate dehydrogenase to alanine aminotransferase ratio as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
Key Points
The aim is to evaluate the LDH/ALT ratio as a prognostic factor in HNSCC patients receiving immune checkpoint inhibitors.
Evaluated serum levels of LDH and ALT in HNSCC patients
Calculated the LDH/ALT ratio
Analyzed correlation with clinical outcomes
LDH/ALT ratio is an independent prognostic biomarker
Higher ratios indicate poorer outcomes
Predictive of responses to immune checkpoint inhibitors
Abstract
The LDH/ALT ratio is an independent prognostic biomarker in HNSCC patients receiving ICIs.